Physicians at New Haven, Conn.-based Smilow Cancer Hospital have performed the world's first multi-target radiotherapy treatment for a patient with metastatic Stage 4 cancer.
The treatment combined SCINTIX biology-guided radiotherapy with "conventional" stereotactic body radiotherapy to simultaneously target the patient's lung tumor and a solid tumor located in another area of the body, according to a Sept. 5 news release shared with Becker's. The hospital is part of Yale New Haven Health.
SCINTIX radiotherapy uses positron emission tomography data and reacts to a lung or bone tumor's motion during treatment, allowing radiation to be delivered more precisely. At the same time, stereotactic body radiotherapy can target a solid tumor in a different location.
The multi-target treatment is delivered in five fractions or fewer, the release said.